← 產業報告目錄
Orphan Drugs Market Size, Share & Trends Analysis Report By Drug Type (Biological, Non-Biological), By Top Selling Drugs, By Therapy Area (Oncology, Blood, Central Nervous System, Endocrine, Respiratory, Immunomodulatory, Other Disease Types), By Region, And By Segment Forecasts, 2025-2034
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-01-11頁數 180報告編號 INSIGHTACE-2e9f44ec88
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
The worldwide Orphan Drugs Market stood at USD 213.6 Billion in 2024, and is forecasted to reach USD 669.5 Billion by 2034, recording a CAGR of 12.2% from 2025 through 2034.
Orphan Drugs covers recognized as the potential therapeutic market because diseases which are covered under the market are life-threatening diseases to treat disease which are very rare. Rapid advancements and evolving end-user preferences are reshaping how healthcare entities approach this space.
Market momentum is propelled by mounting requirement advanced solutions, favorable regulatory frameworks, and robust investment in research and development across major economies.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region forecasted to deliver the strongest growth trajectory through the forecast period, propelled by demographic shifts and policy support.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
The research provides an in-depth evaluation of market forces, competitive positioning, segmental dynamics, and regional trends, equipping stakeholders with actionable intelligence for the forecast period.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Orphan Drugs Market Snapshot
Chapter 4. Global Orphan Drugs Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Industry Analysis – Porter's Five Forces Analysis
4.6. Competitive Landscape & Market Share Analysis
4.7. Clinical Trial/Pipeline Analysis Snapshot
4.8. COVID 19 Impact on Pharmaceutical Industry
Chapter 5. Market Segmentation 1: Drug Types Estimates & Trend Analysis
5.1. Drug Types & Market Share, 2024 & 2034
5.2. Market Size (Value) & Forecasts and Trend Analyses, 2021 to 2034 for the following Drug Types:
5.2.1. Biological
5.2.2. Non-Biological
Chapter 6. Market Segmentation 2: Top Selling Drugs & Trend Analysis
6.1. Top Selling Drugs & Market Share, 2024 & 2034
6.2. Market Size (Value)& Forecasts and Trend Analyses, 2021 to 2034 for the following Top Selling Drugs:
6.2.1. Revlimid
6.2.2. Rituxan
6.2.3. Copaxone
6.2.4. Opdivo
6.2.5. Keytruda
6.2.6. Imbruvica
6.2.7. Avonex
6.2.8. Sensipar
6.2.9. Soliris
6.2.10. Other Top Selling Drugs
Chapter 7. Market Segmentation 3: Therapy Area & Trend Analysis
7.1. Therapy Area & Market Share, 2024 & 2034
7.2. Market Size (Value)& Forecasts and Trend Analyses, 2021 to 2034 for the following Therapy Area
7.2.1. Oncology
7.2.2. Blood
7.2.3. Central Nervous System
7.2.4. Endocrine
7.2.5. Cardiovascular
7.2.6. Respiratory
7.2.7. Immunomodulatory
7.2.8. Other Disease Types
Chapter 8. Orphan Drugs Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Orphan Drugs Market revenue (US$ Million) estimates and forecasts Drug Types, 2021-2034
8.1.2. North America Orphan Drugs Market revenue (US$ Million) estimates and forecasts by Top Selling Drugs, 2021-2034
8.1.3. North America Orphan Drugs Market revenue (US$ Million) estimates and forecasts Therapy Area, 2021-2034
8.1.4. North America Orphan Drugs Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
8.1.4.1. U.S.
8.1.4.2. Canada
8.2. Europe
8.2.1. Europe Orphan Drugs Market revenue (US$ Million) estimates and forecasts by Drug Types, 2021-2034
8.2.2. Europe Orphan Drugs Market revenue (US$ Million) estimates and forecasts by Top Selling Drugs, 2021-2034
8.2.3. Europe Orphan Drugs Market revenue (US$ Million) estimates and forecasts Therapy Area, 2021-2034
8.2.4. Europe Orphan Drugs Market revenue (US$ Million) by country, 2021-2034
8.2.4.1. Germany
8.2.4.2. Poland
8.2.4.3. France
8.2.4.4. Italy
8.2.4.5. Spain
8.2.4.6. UK
8.2.4.7. Rest of Europe
8.3. Asia Pacific
8.3.1. Asia Pacific Orphan Drugs Market revenue (US$ Million) Drug Types, 2021-2034
8.3.2. Asia Pacific Orphan Drugs Market revenue (US$ Million) estimates and forecasts by Top Selling Drugs, 2021-2034
8.3.3. Asia Pacific Orphan Drugs Market revenue (US$ Million) estimates and forecasts Therapy Area, 2021-2034
8.3.4. Asia Pacific Orphan Drugs Market revenue (US$ Million) by country, 2021-2034
8.3.4.1. China
8.3.4.2. India
8.3.4.3. Japan
8.3.4.4. Australia
8.3.4.5. Rest of Asia Pacific
8.4. Latin America
8.4.1. Latin America Orphan Drugs Market revenue (US$ Million) Drug Types, 2021-2034
8.4.2. Latin America Orphan Drugs Market revenue (US$ Million) estimates and forecasts by Top Selling Drugs, 2021-2034
8.4.3. Latin America Orphan Drugs Market revenue (US$ Million) estimates and forecasts Therapy Area, 2021-2034
8.4.4. Latin America Orphan Drugs Market revenue (US$ Million) by country, 2021-2034
8.4.4.1. Brazil
8.4.4.2. Rest of Latin America
8.5. MEA
8.5.1. MEA Orphan Drugs Market revenue (US$ Million) estimates and forecasts Drug Types, 2021-2034
8.5.2. MEA Orphan Drugs Market revenue (US$ Million) estimates and forecasts by Top Selling Drugs, 2021-2034
8.5.3. MEA Orphan Drugs Market revenue (US$ Million) estimates and forecasts Therapy Area, 2021-2034
8.5.4. MEA revenue Orphan Drugs Market revenue (US$ Million) by country, (US$ Million) 2021-2034
8.5.4.1. South Africa
8.5.4.2. Rest of MEA
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Bristol-Myers Squibb Company
9.2.2. Celgene Corporation
9.2.3. F. Hoffmann-La Roche Ltd
9.2.4. Amgen
9.2.5. Biogen
9.2.6. Bayer
9.2.7. Novartis AG
9.2.8. GlaxoSmithKline plc
9.2.9. Johnson & Johnson
9.2.10. AbbVie Inc
9.2.11. Eli Lilly and Company
9.2.12. Alexion Pharmaceuticals
9.2.13. Shire
9.2.14. Novo Nordisk
9.2.15. AstraZeneca
9.2.16. Eisai
9.2.17. Daiichi Sankyo
9.2.18. Merck
9.2.19. Teva Pharmaceutical Industries
9.2.20. Actelion Pharmaceuticals Ltd.
9.2.21. Aegerion Pharmaceuticals
Other Prominent Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們